A phase I monotherapy study to evaluate the safety, tolerability and immunogenicity of a candidate next generation lipid nanoparticle (LNP) mRNA vaccine against SARS-CoV-2 (NeomiVac) in UK healthy adult volunteers
100 Clinical Results associated with Neovac Ltd.
0 Patents (Medical) associated with Neovac Ltd.
100 Deals associated with Neovac Ltd.
100 Translational Medicine associated with Neovac Ltd.